| Document |
Document Title |
|
WO/2023/120552A1 |
The present specification discloses a reduced coenzyme Q10 product which does not require the formulation of reduced coenzyme Q10 and in which the oxidation of reduced coenzyme Q10 is suppressed. Also, the present specification discloses...
|
|
WO/2023/120558A1 |
The present specification discloses a method for storing reduced coenzyme Q10 (QH), the method being capable of suppressing oxidation. The first embodiment of the present invention relates to a method for storing QH, the method includi...
|
|
WO/2023/120557A1 |
The present description discloses a packaged body of reduced coenzyme Q10, which eliminates the need for formulating the reduced coenzyme Q10 into a preparation, does not undergo the oxidation of the reduced coenzyme Q10 and can be store...
|
|
WO/2023/120555A1 |
The present description discloses a favorable means for suppressing oxidation of reduced coenzyme Q10 (QH) without requiring formulation of QH. At least one embodiment of the present invention relates to a method for storing reduced co...
|
|
WO/2023/120553A1 |
The present description discloses a preferred means for preventing the oxidation of reduced coenzyme Q10 (QH) without requiring the formulation of QH into a preparation. One or more embodiments of the present invention relates to: a me...
|
|
WO/2023/102759A1 |
The present invention relates to a composition comprising 2-amylenyl-anthraquinones and to its preparation method. The composition can be used for producing a composition comprising 2-amylanthraquinone isomers with specific molar ratio.
|
|
WO/2023/100152A1 |
The present disclosure provides compositions containing glutathione, coenzyme Q10 (CoQ10), pyrroloquinoline quinone, and/or iron binding glycoproteins. Formulations comprising the compositions described herein are also provided. Methods ...
|
|
WO/2023/099154A1 |
Anthracene-9,10-dione derivatives are capable of producing bleach-active species under irradiation of visible light, which lead to an increase of the bleaching power during the washing of textiles.
|
|
WO/2023/096111A1 |
The present application relates to a novel quinizarine derivative, wherein the quinizarine derivative has a bromodomain extra-terminal (BET) protein inhibition ability, and thus can be used in a pharmaceutical composition for preventing ...
|
|
WO/2023/090313A1 |
The purpose of the present invention is to newly discover a transient receptor potential ankyrin 1 (TRPA1) agonist that exhibits an action for increasing the amount of food ingested, to provide a novel agonist of TRPA1, or to provide a n...
|
|
WO/2023/081725A1 |
Provided herein are compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. Also provided a...
|
|
WO/2023/073080A1 |
The present invention relates to a process for preparing aromatic acyl derivatives of formula (I) using methanesulfonic acid. The invention further relates to methods for preparing biological active ingredients, such as paracetamol.
|
|
WO/2023/059640A1 |
The present disclosure provides compounds, compositions containing such compounds, and methods of designing, developing, producing and preparing compounds represented by general Formula (I), including pharmaceutically acceptable salts th...
|
|
WO/2023/031841A1 |
The present disclosure relates to a novel process for the synthesis of stereospecific compounds of Vitamin K2 group in general and Vitamin K2-7, in particular. It also discloses novel intermediates useful in the synthesis of stereospecif...
|
|
WO/2023/011668A1 |
Disclosed in the present invention are a perinaphthenone compound and the use thereof. The compound can bind to E3 ubiquitin ligase tripartite motif 25 (TRIM25), thereby facilitating the recognition of TRIM25 to a pathogen and inducing p...
|
|
WO/2023/009610A1 |
The application discloses methods useful for the synthesis of racemic, scalemic, and chiral alpha-tocotrienol quinone, including synthetic intermediates and methods for making said synthetic intermediates.
|
|
WO/2023/285509A1 |
The present invention relates to a process for the preparation of a compound having formula (I) wherein R is selected from the group consisting of: halogen, (C1-C6)alkoxy, (C1-C6)alkyl, halo(C1-C6)alkyl, and halo(C1-C6)alkoxy, said proce...
|
|
WO/2022/261347A1 |
The disclosure provides various new and existing compounds for use alone or as formulated in a composition (e.g., medicaments) and related methods and uses for treating, preventing, inhibiting, ameliorating or delaying the onset of a dis...
|
|
WO/2022/257994A1 |
Disclosed are a cryptotanshinone derivative, a preparation method therefor and an application thereof in anti-myocardial fibrosis. The new cryptotanshinone derivative has a structural formula of (I). Preliminary experimental results show...
|
|
WO/2022/254047A1 |
The invention generally relates to emodin derivatives of general structure (I), to pharmaceutical compositions comprising same and to their uses in medicine, especially in the treatment of bacterial or viral infections. The invention fur...
|
|
WO/2022/233417A1 |
The present invention relates to the manufacture of benzoquinones, in particular to the manufacture of a potassium salt of a benzoquinone, such as 2,5-dihydroxy-l,4-benzoquinone di-potassium salt. The potassium salt of a benzoquinone is ...
|
|
WO/2022/216359A1 |
An analytical method is disclosed that includes the steps of: providing a sample potentially containing a chiral analyte that can exist in stereoisomeric forms; providing a probe selected from the group consisting of quinones and analogs...
|
|
WO/2022/204811A1 |
The present application relates to water-soluble formulations. More specifically, the present application relates to formulations comprising at least one of Coenzyme-Q10 and an ashwagandha root extract and a solubilizing agent. More spec...
|
|
WO/2022/202213A1 |
The purpose of the present disclosure is to provide a method for efficiently obtaining reduced coenzyme Q10 crystals of Form II that is a stable crystal form, particularly reduced coenzyme Q10 crystals of Form II having excellent oxidati...
|
|
WO/2022/202215A1 |
The purpose of the present invention is to provide a method which is for producing form-II type reduced coenzyme Q10 crystals or a crystalline solid thereof, and which enables stable production of form-II type reduced coenzyme Q10 crysta...
|
|
WO/2022/202214A1 |
The purpose of the present disclosure is to provide a production method that is for reduced coenzyme Q10 Form-II type crystals or a crystalline solid thereof and that enables excellent filtering ability of a slurry containing reduced coe...
|
|
WO/2022/192633A1 |
The present disclosure provides for a pharmaceutical composition comprising ubiquinone-5 (UB5) and method of use thereof. The present disclosure relates to ubiquinone-5 used as an anesthetic, sedative agent, hypnotic agent, or combinatio...
|
|
WO/2022/188233A1 |
The present invention relates to the use of a TMPD-TXBQ cocrystal material in laser ignition. TMPD-TXBQ of the present invention can be applied to the laser ignition of an energetic material as a light-controlled detonating agent. The TM...
|
|
WO/2022/184904A1 |
The present invention relates to a method for the preparation of a compound having formula (I) wherein: • R1, R2, R3, and R4 are in particular H or halogen, • R5 is in particular (C1-C6)alkyl, • R6 is a group of formula -CH=CH2 or ...
|
|
WO/2022/184938A1 |
A compound of formula (I): (I) wherein n is an integer between 0 and 10; Y is hydrogen, halide, mesylate, tosylate, ester, -SPh, -SO2Ph, hydroxyl or protected hydroxyl; with the proviso that if n = 0 or 1, Y is not hydrogen.
|
|
WO/2022/144920A1 |
The present invention discloses Atovaquone prodrugs, process for the preparation of said prodrugs and pharmaceutical compositions comprising Atovaquone prodrugs. Atovaquone prodrugs of the present invention can be used alone, or co-admin...
|
|
WO/2022/129185A1 |
The present invention generally relates to the production of vanillin and related compounds (such as aromatic carboxylic acids, quinones, etc.) involving the oxidative cleavage of aromatic compounds (such as lignin, lignols, cinnamic aci...
|
|
WO/2022/107095A1 |
Disclosed are methods of treating pain, such as headaches, comprising administering an ergotamine and thymoquinone, wherein the ergotamine is selected from the group consisting of BOL-148, lysergic acid diethylamide (LSD), and lysergic a...
|
|
WO/2022/104763A1 |
Provided process for cyclization of 2- (4' -alkylbenzoyl) benzoic acid to corresponding 2-alkylanthraquinone in the presence of an improved zeolite catalyst, which is capable of increasing the conversion of 2- (4' -alkylbenzoyl) benzoic ...
|
|
WO/2022/091123A1 |
The present invention discloses compounds for inhibition of uncontrolled cell proliferation particularly cancer stem cells. Particularly, the invention relates to compounds of Formula (I) to (IV) for the treatment of cancer.
|
|
WO/2022/057603A1 |
The present invention relates to a method for extracting coenzyme Q10 from a fermentation broth of coenzyme Q10, comprising subjecting the fermentation broth of coenzyme Q10 to pre-processing, leaching, crystallization, dissolution, chro...
|
|
WO/2022/051291A2 |
Novel compounds which inhibit DYRK1A activity comprise thymoquinone derivatives including a pair of substituted or unsubstituted six-membered carbon rings selected from phenyl and cyclohexadiene linked by an alkyl or alkenyl linker. Each...
|
|
WO/2022/015181A1 |
The invention relates to a method and intermediate compounds for the preparation of menaquinone MK-7. The method for the preparation of menaquinone MK-7 is characterized in that, it comprises coupling of a compound of formula (11) with a...
|
|
WO/2021/238947A1 |
Disclosed is a method for preparing a quinone compound. The present invention provides a method for preparing a quinone compound, the method comprising the following step: in the presence of a base, subjecting a compound as shown in form...
|
|
WO/2021/234078A1 |
The present invention relates to the photooxidation of 2,3,6-trimethyl- phenol to yield 2,3,5-trimethylbenzoquinone using methylene blue as photo- sensitizer in a solvent mixture of water and alcohols using light of the high wave- length...
|
|
WO/2021/234077A1 |
The present invention relates to the photooxidation of 2,3,5-trimethyl- phenol to yield 2,3,5-trimethylbenzoquinone using methylene blue as photo- sensitizer in a solvent mixture of water and alcohols using light of the high wavelength r...
|
|
WO/2021/234080A1 |
The present invention relates to the photooxidation of phenolic compounds to the respective quinoid compounds using methylene blue as photosensitizer in a solvent mixture of water and alcohols using light of the high wavelength range of ...
|
|
WO/2021/232543A1 |
Disclosed is a method for separating coenzyme Q10 by means of using a supercritical fluid chromatography system, the method comprising: (1) starting a supercritical fluid chromatography system and setting system parameters; (2) once the ...
|
|
WO/2021/202986A1 |
The disclosure provides therapeutic compounds, compositions (e.g., therapeutic agents or medicaments) and methods for preventing or treating mitochondrial disease such as Friedreich's ataxia in a mammalian subject, reducing risk factors,...
|
|
WO/2021/175123A1 |
Disclosed are a 1,4-naphthoquinone compound for resisting novel coronavirus and the medical use thereof. The structure of the compound is as shown in formula (X): (X), wherein R1 is hydrogen, hydroxy, methoxy, ethoxy, benzyloxy, acetylox...
|
|
WO/2021/173658A1 |
The present disclosure provides compounds of formula 1 to inhibit or prevent mitochondrial dysfunction by augmenting mitochondrial function. Mitochondrial dysfunction is the hallmark of a wide range of diseases and disorders. Mitochondri...
|
|
WO/2021/161283A1 |
Described herein are compounds of Formula I: wherein R1-R6 are as described herein, for use in the treatment of a coronavirus infection; a method of inhibiting a coronavirus 3 CL protease, by contacting the 3 CL protease with a compound ...
|
|
WO/2021/156406A1 |
The present invention relates to a process for preparing 8-hydroxy-9,10-dioxo-anthracene-1- carboxylic acid. It also relates to a method for preparing an anthraquinone derivative comprising a step for preparing 8-hydroxy-9,10-dioxo-anthr...
|
|
WO/2021/122437A1 |
The present invention relates to the formation of 2,3,5-trimethylhydro- quinone from 2,3,6-tri¬methyl¬phenol comprising the steps a) the oxidation of 2,3,6-trimethylphenol to 2,3,5-trimethylquinone. b) the reduction of 2,3,5-trimethylq...
|
|
WO/2021/126892A1 |
A method of oxygen scavenging, the method (i) providing an oxygen scavenger composition; and (ii) adding the oxygen scavenger composition to an aqueous feed and/or a hydrocarbon feed of a hydrocarbon processing system.
|
